Therefore, we conducted a retrospective analysis utilizing the most recent clinical data in order to investigate the clinical characteristics and prognosis of patients with de novo stage IV HER2-positive breast cancer, with or without primary site surgery. This evidence concerns the gene ERBB2 and breast carcinoma.